Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Outlook Therapeutics, Inc. (OTLK) Phase 3 Data Supports Approval - Analyst
August 3, 2021 11:54 AM EDTEarlier today, Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA (bevacizumab) - the companys lead drug candidate for treatment of neovascular... More
Outlook Therapeutics Incs. (OTLK) PT Raised to $6 at H.C. Wainwright
August 3, 2021 10:56 AM EDTH.C. Wainwright analyst Douglas Tsao raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $6.00 (from $5.00) while maintaining a Buy rating.
... MoreOutlook Therapeutics (OTLK) Climbs 41%
August 3, 2021 7:43 AM EDTOutlook Therapeutics (NASDAQ: OTLK) Climbs 41%
Earlier Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010... More